Literature DB >> 11383755

Cost-benefit analysis of a Haemophilus influenzae type b meningitis prevention programme in The Philippines.

M R Limcangco1, C L Armour, E G Salole, S J Taylor.   

Abstract

BACKGROUND: Haemophilus influenzae type b (Hib) meningitis is associated with high mortality and serious sequelae in children under 5 years of age. Vaccines which can prevent this infection are available.
OBJECTIVE: To evaluate the costs and benefits of a 3-dose immunisation schedule in Manila, Philippines. PERSPECTIVE: Government and societal perspectives. DESIGN AND PARTICIPANTS: A cost-benefit analysis based on a birth cohort of 100,000 children. The state of health of the cohort with and without a Hib immunisation programme was modelled over a 5-year period. A survey of medical records of patients with Hib in Manila provided data on the extent and cost of sequelae following infection. INTERVENTION: A 3-dose Hib vaccination programme given at ages 2, 3 and 4 months.
RESULTS: The model predicted that vaccinating children against Hib meningitis would prevent 553 cases per year in a birth cohort of 100,000, at a cost of 56,200 Philippine pesos (PHP) [$US1,605; 1998 exchange rate] per case (base case assumptions of 90% vaccine efficacy rate, 95 per 100,000 Hib incidence rate, 85% vaccination coverage). Results from the cost-benefit analyses indicated that the saving to the government would be around PHP39 million ($US1.11 million), and the saving to society would be PHP255 million ($US7.28 million).
CONCLUSION: There would be a positive economic benefit for the Philippine government and for the Filipino society if a Hib vaccination programme was introduced in Manila.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11383755     DOI: 10.2165/00019053-200119040-00006

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  40 in total

1.  A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease.

Authors:  J Eskola; H Käyhty; A K Takala; H Peltola; P R Rönnberg; E Kela; E Pekkanen; P H McVerry; P H Mäkelä
Journal:  N Engl J Med       Date:  1990-11-15       Impact factor: 91.245

2.  Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster.

Authors:  R Booy; P T Heath; M P Slack; N Begg; E R Moxon
Journal:  Lancet       Date:  1997-04-26       Impact factor: 79.321

3.  Haemophilus influenzae type b carriage and immunity four years after receiving the Haemophilus influenzae oligosaccharide-CRM197 (HbOC) conjugate vaccine.

Authors:  M L Barbour; R Booy; D W Crook; H Griffiths; H M Chapel; E R Moxon; D Mayon-White
Journal:  Pediatr Infect Dis J       Date:  1993-06       Impact factor: 2.129

4.  Etiology of acute lower respiratory tract infection in children from Alabang, Metro Manila.

Authors:  T E Tupasi; M G Lucero; D M Magdangal; N V Mangubat; M E Sunico; C U Torres; L E de Leon; J F Paladin; L Baes; M C Javato
Journal:  Rev Infect Dis       Date:  1990 Nov-Dec

5.  The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of the vaccine PRP-OMP.

Authors:  A Harris; D Hendrie; C Bower; J Payne; N de Klerk; F Stanley
Journal:  Med J Aust       Date:  1994-04-18       Impact factor: 7.738

6.  The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex.

Authors:  M Santosham; M Wolff; R Reid; M Hohenboken; M Bateman; J Goepp; M Cortese; D Sack; J Hill; W Newcomer
Journal:  N Engl J Med       Date:  1991-06-20       Impact factor: 91.245

7.  Cost benefit analysis of Haemophilus influenzae type b vaccination programme in Israel.

Authors:  G M Ginsberg; I Kassis; R Dagan
Journal:  J Epidemiol Community Health       Date:  1993-12       Impact factor: 3.710

8.  Safety and immunogenicity of Haemophilus type b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis vaccine in young infants.

Authors:  N Watemberg; R Dagan; Y Arbelli; I Belmaker; A Morag; L Hessel; B Fritzell; A Bajard; L Peyron
Journal:  Pediatr Infect Dis J       Date:  1991-10       Impact factor: 2.129

9.  Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines.

Authors:  M D Decker; K M Edwards; R Bradley; P Palmer
Journal:  J Pediatr       Date:  1992-02       Impact factor: 4.406

10.  Etiology of acute lower respiratory infection in Filipino children under five years.

Authors:  M R Capeding; L T Sombrero; F J Paladin; H Suzuki; Y Numazaki; M C Saniel
Journal:  Southeast Asian J Trop Med Public Health       Date:  1994-12       Impact factor: 0.267

View more
  3 in total

1.  Cost-effectiveness of Haemophilus influenzae type b conjugate vaccine in low- and middle-income countries: regional analysis and assessment of major determinants.

Authors:  Ulla Kou Griffiths; Andrew Clark; Rana Hajjeh
Journal:  J Pediatr       Date:  2013-07       Impact factor: 4.406

2.  The use of cost-effectiveness analysis for pediatric immunization in developing countries.

Authors:  Cindy Low Gauvreau; Wendy J Ungar; Jillian Clare Köhler; Stanley Zlotkin
Journal:  Milbank Q       Date:  2012-12       Impact factor: 4.911

3.  Cost-benefit analysis of haemophilus influenzae type B immunization in Korea.

Authors:  Sangjin Shin; Young-jeon Shin; Moran Ki
Journal:  J Korean Med Sci       Date:  2008-04       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.